Taysha Gene Therapies, Inc. Ratios

Ratios Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Profitability
EBT Margin 153,503.57%12,221.50%-6,634.53%-478.06%-1,015.49%
EBIT Margin 153,578.57%12,133.54%-6,492.69%-468.83%-1,097.55%
EBITDA Margin 153,578.57%12,133.54%-6,492.69%-468.83%-1,097.55%
Operating Margin 153,578.57%12,133.54%-6,492.69%-468.83%-1,097.55%
Net Margin 214,325.00%12,221.50%-6,635.25%-722.06%-1,071.62%
FCF Margin 110,039.29%9,267.93%-4,356.87%-497.62%-979.23%
Efficiency
Assets Average 149.50M166.55M
Equity Average 37.94M73.23M
Invested Capital 0.95M74.94M111.53M
Asset Utilization Ratio 0.100.05
Leverage & Solvency
Interest Coverage Ratio -0.00M-121.34-42.77-14.49-896.66
Debt to Equity 40.010.540.61
Debt Ratio 0.300.230.27
Equity Ratio 0.010.430.45
Times Interest Earned -0.00M-121.34-42.77-14.49-896.66
Valuation
Enterprise Value 1,002.19M448.22M53.24M186.53M192.62M
Market Capitalization 1,002.19M448.22M141.12M330.92M332.10M
Return Ratios
Return on Sales 122.21%-66.35%-4.78%-10.15%
Return on Capital Employed -0.64%-0.65%
Return on Assets -0.49%-0.51%
Return on Equity -1.95%-1.16%